According to Reuters on September 24, Sanofi CEO Paul Hudson said in an interview on Monday that the company is expected to achieve strong growth through a variety of new drugs, and will not face the issue of best-selling products expiring and high costs like some competitors. The company has 12 potential heavy assets in the fields of immunology and vaccines, and will not have any major patents expiring before the end of this century. The company has not yet entered the lucrative obesity drug market, Hudson said Sanofi does not want to create generics of GLP-1 drugs like Ozempic or Mounjaro, 'we have some undisclosed projects internally and are investing in opportunities with third parties.' Regarding the consumer medical care department Opella, Hudson stated they are considering splitting, selling the department, or conducting an IPO.
赛诺菲CEO相信公司有望通过多种新药实现增长
The CEO of Sanofi believes that the company is expected to achieve growth through a variety of new drugs.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.